These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 22926515

  • 1. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP, Marais R.
    Oncogene; 2013 Jun 27; 32(26):3207-12. PubMed ID: 22926515
    [Abstract] [Full Text] [Related]

  • 2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.
    Nature; 2010 Mar 18; 464(7287):427-30. PubMed ID: 20179705
    [Abstract] [Full Text] [Related]

  • 3. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.
    Nature; 2010 Mar 18; 464(7287):431-5. PubMed ID: 20130576
    [Abstract] [Full Text] [Related]

  • 4. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
    Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R, Higgins S, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner L, Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS, Engelman JA, Stuart DD, Cooke VG, Caponigro G.
    Clin Cancer Res; 2021 Apr 01; 27(7):2061-2073. PubMed ID: 33355204
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.
    Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.
    Cope NJ, Novak B, Liu Z, Cavallo M, Gunderwala AY, Connolly M, Wang Z.
    J Biol Chem; 2020 Feb 21; 295(8):2407-2420. PubMed ID: 31929109
    [Abstract] [Full Text] [Related]

  • 9. No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.
    Kumagai A, Namba H, Takakura S, Inamasu E, Saenko VA, Ohtsuru A, Yamashita S.
    Endocr J; 2006 Oct 21; 53(5):615-20. PubMed ID: 16896265
    [Abstract] [Full Text] [Related]

  • 10. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA.
    Endocrinology; 2006 Feb 21; 147(2):1014-9. PubMed ID: 16254036
    [Abstract] [Full Text] [Related]

  • 11. Allosteric activation of functionally asymmetric RAF kinase dimers.
    Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS.
    Cell; 2013 Aug 29; 154(5):1036-1046. PubMed ID: 23993095
    [Abstract] [Full Text] [Related]

  • 12. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 13. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
    Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE.
    Cancer Cell; 2013 May 13; 23(5):594-602. PubMed ID: 23680146
    [Abstract] [Full Text] [Related]

  • 14. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
    Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS.
    Proc Natl Acad Sci U S A; 2011 Apr 12; 108(15):6067-72. PubMed ID: 21441104
    [Abstract] [Full Text] [Related]

  • 15. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C, Estrada C, Barbotin C, Larcher M, Garancher A, Leloup J, Beermann F, Baccarini M, Pouponnot C, Larue L, Eychène A, Druillennec S.
    Nat Commun; 2017 May 12; 8():15262. PubMed ID: 28497782
    [Abstract] [Full Text] [Related]

  • 16. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE.
    J Biol Chem; 2012 Dec 07; 287(50):41797-807. PubMed ID: 23076151
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV, Hövermann D, Müller A, Wagner HJ, Weber W, Radziwill G.
    Sci Rep; 2016 Mar 30; 6():23713. PubMed ID: 27025703
    [Abstract] [Full Text] [Related]

  • 19. Structural snapshots of RAF kinase interactions.
    Rezaei Adariani S, Buchholzer M, Akbarzadeh M, Nakhaei-Rad S, Dvorsky R, Ahmadian MR.
    Biochem Soc Trans; 2018 Dec 17; 46(6):1393-1406. PubMed ID: 30381334
    [Abstract] [Full Text] [Related]

  • 20. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P, Laster K, Jia X, Dong Z, Liu K.
    Mol Cancer; 2023 Dec 18; 22(1):208. PubMed ID: 38111008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.